Cassava Sciences, Inc.

SAVA

US14817C1071

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
21.19 ^USD	-0.38%		-18.84%	-5.86%

Mar. 25	Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	MT
Mar. 25	Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	CI

Cassava Sciences, Inc.(NasdaqCM:SAVA) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Cassava Sciences, Inc.

Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	Mar. 25	MT
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	Mar. 25	CI
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer?s Disease Dementia	Feb. 07	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000 Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell Small Cap Completeness Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell Small Cap Comp Growth Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000 Growth Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000E Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000E Growth Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Dynamic Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Dynamic Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Growth-Dynamic Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth-Dynamic Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Growth Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from S&P TMI Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from S&P Pharmaceuticals Select Industry Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from S&P Global BMI Index	Jan. 08	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) added to S&P Pharmaceuticals Select Industry Index	Dec. 21	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) added to S&P TMI Index	Dec. 21	CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) added to S&P Global BMI Index	Dec. 21	CI

Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.

Sector

Biotechnology & Medical Research

Calendar

2024-04-28 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

21.19 USD

Average target price

124 USD

Spread / Average Target

+485.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CASSAVA SCIENCES, INC.	-5.86%	916M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-0.44%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-7.45%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs